Abstract
The pharmacokinetic profiles of triamterene and hydroxytriamterene sulfuric acid ester, the major metabolite of triamterene, were studied in six normal male volunteers using a newly developed specific HPLC analytical method. Following a 100 mg oral dose of triamterene, the plasma concentration time course of the sulfate conjugate parallels that of triamterene in all subjects, but concentrations of the metabolite were more than 10 times higher than unchanged triamterene concentrations at identical sampling times. Interestingly, the renal clearance of the sulfate conjugate was less than that of triamterene. These characteristic features of triamterene disposition were fitted to a compartment model incorporating a first-pass metabolic process. Unbound fractions of triamterene and metabolite in plasma were 0.39 and 0.10 (mean of 6 subjects), respectively. The low unbound fraction of the metabolite in plasma most probably accounts for the low renal clearance of the sulfate conjugate as compared with triamterene.
Similar content being viewed by others
References
E. J. Thompson, E. Torres, S. J. Grosberg, and M. M. Maldonado. Effect of triamterene on potassium excretion in cirrhotic patients receiving furosemide.Clin. Pharmacol. Ther. 21:392–394 (1976).
H. Krauf, W. Möhrke, E. Mutschier, and K. D. Völger. Zur Bioverf/:ugbarkeit von Hydrochlorothiazid und Triamteren aus Fertigarzneimitteln.Arzneim. Forsch./ Drug Res. 29:1001–1004 (1980).
K. B. Hansen and A. D. Bender. Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination.Clin. Pharmacol. Ther. 8:392–399 (1966).
G. H. Mudge. Diuretics and other agents employed in the mobilization of edema. InThe Pharmacological Basis of Therapeutics, 6th ed., A. G. Gilman, L. S. Goodman, and A. Gilman (eds.). Macmillan, New York, 1980, pp. 157–183.
G. Leilich, H. Knauf, E. Mutschler, and K. D. Völger. Influence of triamterene and hydroxytriamterene sulfuric acid ester on diuresis and saluresis in rats after oral and intravenous application.Arzneim. Forsch./ Drug Res. 30:949–953 (1980).
A. W. Pruitt, J. S. Winkel, and P. G. Dayton. Variations in the fate of triamterene.Clin. Pharmacol. Ther. 21:610–619 (1977).
U. Gundert-Remy, D. Kenne, E. Weber, H. E. Geissler, B. Grebian, and E. Mutschler. Plasma and urinary levels of triamterene and certain metabolites after oral administration to man.Eur. J. Clin. Pharmacol. 16:39–44 (1979).
E. T. Lin, F. Sörgel, J. Hasegawa, and L. Z. Benet. HPLC analysis of triamterene and metabolites in plasma. Abstract, Academy of Pharmaceutical Sciences Meeting, San Antonio, Texas (November 1980).
D. E. Smith, E. T. Lin, and L. Z. Benet. Absorption and disposition of furosemide in healthy volunteers, measured with a metabolic-specific assay.Drug Metab. Dispos. 8:337–342 (1980).
N. H. G. Holford. MKMODEL, inPublic Procedures Notebook, H. M. Perry and J. J. Wood (eds.). Bolt Beranek and Newman, Cambridge, Mass., 1982.
P. A. Castleman, C. H. Russel, F. N. Webb, C. A. Hollister, J. R. Siegel, S. R. Zdonik, and D. M. Fram. The implementation of the PROPHET system,Natl. Comput. Conf. Exposition Proc. 43:457–468 (1974).
G. D. Knott. MLAB—a mathematical modeling tool.Comput. Programs Biomed. 10:271–280 (1979).
A. Akaike. A new look at the statistical model identification.IEEE Trans. Automat. Control 19:716–723 (1973).
K. Yamaoka, T. Nakagawa, and T. Uno. Application of Akaike's Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations.J. Pharmacokinet. Biopharm. 6:165–175 (1978).
H. G. Boxenbaum, S. Riegelman, and R. M. Elashoff. Statistical estimations in pharmacokinetics.J. Pharmacokinet. Biopharm. 2:123–148 (1974).
K. S. Pang and J. R. Gillette. Kinetics of metabolite formation and elimination in the perfused rat liver preparation: differences between the elimination of preformed acetaminophen and acetaminophen formed from phenacetin.J. Pharmacol Exp. Ther. 207:178–194 (1978).
K. S. Pang and J. R. Gillette. Sequential first-pass elimination of a metabolite derived from a precursor.J. Pharmacokinet. Biopharm. 7:275–290 (1979).
S. Øie and T. N. Tozer. Effect of altered plasma protein binding on apparent volume of distribution.J. Pharm. Sci. 68:1203–1205 (1979).
K. M. Kessler, R. C. Leech, and J. F. Spann. Blood collection techniques, heparin and quinidine proten binding.Clin. Pharmacol. Ther. 25:204–210 (1979).
R. H. Cotham and D. Shand. Spuriously low plasma propranolol concentrations resulting from blood collection methods.Clin. Pharmacol. Ther. 18:535–538 (1975).
K. M. Piafsky. Disease-induced changes in the plasma binding of basic drugs.Clin. Pharmacokin. 5:246–262 (1980).
S. Øie and L. Z. Benet. Altered drug disposition in disease states.Annu. Rep. Med. Chem. 15:277–287 (1980).
Author information
Authors and Affiliations
Additional information
Supported in part by NIH Grant AM20884 and funds from Mylan Pharmaceuticals.
Rights and permissions
About this article
Cite this article
Hasegawa, J., Lin, E.T., Williams, R.L. et al. Pharmacokinetics of triamterene and its metabolite in man. Journal of Pharmacokinetics and Biopharmaceutics 10, 507–523 (1982). https://doi.org/10.1007/BF01059034
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01059034